de Jong Hanna K, Grobusch Martin P
Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Infection and Immunity, Amsterdam Public Health, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Institute of Tropical Medicine & Deutsches Zentrum Für Infektionsforschung, University of Tübingen, Tübingen, Germany.
Trop Dis Travel Med Vaccines. 2024 Jan 15;10(1):2. doi: 10.1186/s40794-023-00212-x.
For decades, immunoglobulin preparations have been used to prevent or treat infectious diseases. Since only a few years, monoclonal antibody applications (mAbs) are taking flight and are increasingly dominating this field. In 2014, only two mAbs were registered; end of October 2023, more than ten mAbs are registered or have been granted emergency use authorization, and many more are in (pre)clinical phases. Especially the COVID-19 pandemic has generated this surge in licensed monoclonal antibodies, although multiple phase 1 studies were already underway in 2019 for other infectious diseases such as malaria and yellow fever. Monoclonal antibodies could function as prophylaxis (i.e., for the prevention of malaria), or could be used to treat (tropical) infections (i.e., rabies, dengue fever, yellow fever). This review focuses on the discussion of the prospects of, and obstacles for, using mAbs in the prevention and treatment of (tropical) infectious diseases seen in the returning traveler; and provides an update on the mAbs currently being developed for infectious diseases, which could potentially be of interest for travelers.
几十年来，免疫球蛋白制剂一直被用于预防或治疗传染病。仅仅在几年前，单克隆抗体应用（mAbs）开始兴起，并越来越主导这一领域。2014年，仅有两种单克隆抗体注册；到2023年10月底，有十多种单克隆抗体已注册或获得紧急使用授权，还有更多处于（临床前）阶段。特别是新冠疫情推动了已获许可的单克隆抗体的激增，尽管在2019年就已经针对疟疾和黄热病等其他传染病开展了多项1期研究。单克隆抗体可作为预防手段（即预防疟疾），或用于治疗（热带）感染（即狂犬病、登革热、黄热病）。本综述重点讨论在预防和治疗返回旅行者中所见的（热带）传染病方面使用单克隆抗体的前景和障碍；并提供了目前正在开发的、可能对旅行者有潜在意义的用于传染病的单克隆抗体的最新情况。
